Biophytis Valuation
Is 6XB2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6XB2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6XB2's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6XB2's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6XB2?
Key metric: As 6XB2 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 6XB2's PB Ratio? | |
|---|---|
| PB Ratio | -0.7x |
| Book | -€3.86m |
| Market Cap | €2.85m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 6XB2's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
T5O bioXXmed | 13.2x | n/a | €1.4m |
CNW co.don | 1x | n/a | €6.5m |
MDG1 Medigene | 1.2x | -4.1% | €22.6m |
VSC 4SC | 44x | n/a | €49.1m |
6XB2 Biophytis | n/a | 18.5% | €2.9m |
Price-To-Book vs Peers: 6XB2 has negative equity and a Price-To-Book Ratio (-0.7x) compared to the peer average (3.6x).
Price to Book Ratio vs Industry
How does 6XB2's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: 6XB2 has negative equity and a Price-To-Book Ratio (-0.7x) compared to the European Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 6XB2's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 6XB2's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.74
7D
1.9%
1Y
-7.4%
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%